Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-003049-13
    Sponsor's Protocol Code Number:7347
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2022-06-23
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2019-003049-13
    A.3Full title of the trial
    EEG-MRI study of the effect of methylphenidate on neural mechanisms in adult patients with ADHD with or without mood disorders:
    A randomized controlled trial versus placebo.
    Etude EEG-IRM de l'effet du méthylphénidate sur les mécanismes neuronaux chez les patients adultes ayant un TDAH avec ou sans troubles de l'humeur :
    une étude contrôlée randomisée versus placebo.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    EEG-MRI study of the effect of methylphenidate on neural mechanisms in adult patients with ADHD with or without mood disorders:
    A randomized controlled trial versus placebo.
    Etude EEG-IRM de l'effet du méthylphénidate sur les mécanismes neuronaux chez les patients adultes ayant un TDAH avec ou sans troubles de l'humeur :
    une étude contrôlée randomisée versus placebo.
    A.3.2Name or abbreviated title of the trial where available
    ImAteM-TDA
    A.4.1Sponsor's protocol code number7347
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorHôpitaux Universitaires de Strasbourg
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportHôpitaux Universitaires de Strasbourg
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationHôpitaux Universitaires de Strasbourg
    B.5.2Functional name of contact pointSarah HUSTACHE
    B.5.3 Address:
    B.5.3.1Street Address1, Place de l'Hôpital
    B.5.3.2Town/ cityStrasbourg
    B.5.3.3Post code67091
    B.5.3.4CountryFrance
    B.5.6E-maildpidrci@chru-strasbourg.fr
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name RITALINE® 10 mg
    D.2.1.1.2Name of the Marketing Authorisation holderNOVARTIS PHARMA S.A.S.
    D.2.1.2Country which granted the Marketing AuthorisationFrance
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Attention Deficit Hyperactivity Disorder (ADHD)
    Trouble du Déficit de l'Attention avec Hyperactivité (TDAH)
    E.1.1.1Medical condition in easily understood language
    Attention Disorder
    Trouble de l'attention
    E.1.1.2Therapeutic area Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine whether methylphenidate has a different impact on the brain circuits associated with cognitive functions in the two clinical populations studied (adult ADHD patients and patients with attention deficit post-mood disorder) and compared to controls.
    Déterminer si le méthylphénidate impacte différemment les circuits cérébraux associés à des fonctions cognitives dans les deux populations cliniques étudiées (patients TDAH adultes et patients avec déficit attentionnel post trouble de l'humeur) et en comparaison aux témoins.
    E.2.2Secondary objectives of the trial
    1- To determine the effect of methylphenidate on the basal cerebral flow in the two clinical populations and in the controls (healthy subjects).
    2- Determine if methylphenidate has a different impact on cognitive performance in the two clinical populations studied and compared to controls (healthy subjects).
    3- Confirm the effect of methylphenidate on the maintenance of cortical awakening.
    4- Distinguish the brain networks impacted by methylphenidate (maintenance of attention or inhibition) with MRI and EEG.
    1- Déterminer l'effet du méthylphénidate sur le débit cérébral de base dans les deux populations cliniques et chez les témoins (sujets sains).
    2- Déterminer si le méthylphénidate a un impact différent sur les performances cognitives dans les deux populations cliniques étudiées et en comparaison aux témoins (sujets sains).
    3- Confirmer l'effet du méthylphénidate sur le maintien de l'éveil cortical.
    4- Distinguer les réseaux cérébraux impactés par le méthylphénidate (maintien de l'attention ou inhibition) avec l'IRM et l'EEG.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Common criteria for all groups:
    - Subject (male or female) aged 18 to 60 years
    - Subject affiliated to a social health insurance plan, or beneficiary / beneficiary of such a plan
    - Able to understand the objectives and risks of the research and to give dated and signed informed consent
    - Subject who has been informed of the results of the prior medical examination
    - Subject with a "health pass" in relation to the SARS-Cov2 pandemic as defined by current legislation, if applicable
    - Subject agreeing not to consume narcotics during the study (except tobacco and alcohol)
    - For a woman of childbearing age:
    *blood pregnancy test prescribed at inclusion, the result of which must be negative before taking the study treatment
    *effective contraception throughout the study
    *and agreement to perform a urine pregnancy test before each MRI

    Group A: ADHD patients without associated mood disorder (ADHD-P)
    - Diagnosis of ADHD according to DSM-5 (in particular criterion B: presence of symptoms before the age of 12 years) NB: the diagnosis was not necessarily made at this age.
    - Subjects benefiting or not from a methylphenidate treatment

    Group B: patients with attention deficit due to/accentuated by mood disorders (ADHD-HD)
    - Association of ADHD symptoms with attentional disorders according to the combination of the following criteria:
    * DSM-5 diagnosis of recurrent depressive disorder or bipolar disorder
    *Currently euthymic, i.e., a QIDS-16 depression score < 6 (Appendix 1) and a YRMS mania score < 6 (Appendix 2), and clinically stabilized for at least 6 weeks prior to inclusion (stable treatment and out of acute phase). NB: for QIDS item 10 (concentration/decision making, score only decision making)
    *Criterion A of adult ADHD according to DSM-5 (at least 5 symptoms of inattention and/or hyperactivity/impulsivity)
    *Absence of Criterion D in childhood, adolescence and prior to mood disorders (i.e., absence of significant impact with reduced social, academic or occupational functioning)
    *Criterion D present (symptoms have a significant impact with reduced social, academic or occupational functioning)
    - Whether or not the subject is receiving treatment for mood disorders that is approved for:
    *mood stabilizers (lithium, valproate, lamotrigine, oxcarbazepine),
    *antidepressants (SSRIs, SNRIs ≤150mg/d venlafaxine and ≤60mg/d duloxetine), benzodiazepines at stable doses for more than one month (maximum daily dose of 10mg diazepam equivalent).
    - Subjects with or without methylphenidate treatment

    Group C: healthy control subjects
    - Subjects with no psychiatric or neurological history
    Critères communs à tous les groupes :
    - Sujet (homme ou femme) âgé(e) de 18 à 60 ans
    - Sujet affilié à un régime de protection sociale d’assurance maladie, ou bénéficiaire / ayant-droit d’un tel régime
    - Sujet apte à comprendre les objectifs et les risques liés à la recherche et à donner un consentement éclairé daté et signé
    - Sujet ayant été informé des résultats de la visite médicale préalable
    - Sujet disposant d’un « pass sanitaire » en relation avec la pandémie SARS-Cov2 tel que défini par la législation en vigueur, si applicable
    - Sujet acceptant de ne pas consommer de produits stupéfiants pendant la durée de l’étude (à l’exception du tabac et de l’alcool)
    - Pour une femme en âge de procréer :
    *test de grossesse sanguin prescrit à l’inclusion et dont le résultat devra être négatif avant toute prise du traitement à l’étude
    *contraception efficace tout au long de l’étude
    *et acceptation de réaliser un test de grossesse urinaire avant chaque IRM

    Groupe A : patients TDAH sans trouble de l'humeur associé (TDAH-P)
    - Diagnostic de TDAH selon DSM-5 (notamment critère B : présence de symptômes avant l'âge de 12 ans) NB: le diagnostic n'a pas été forcément posé à cet âge.
    - Sujet bénéficiant ou non d'un traitement par méthylphénidate
    Groupe B : patients avec déficit attentionnel suite à/accentué par troubles de l'humeur (TDAH-TH)
    - Association de symptômes TDAH avec troubles attentionnels selon l'association des critères suivants :
    *Diagnostic de trouble dépressif récurrent ou trouble bipolaire selon le DSM-5
    *Actuellement euthymique, c'est à dire un score de dépression à la QIDS-16 < 6 (Annexe 1) et un score de manie à la YRMS < 6 (Annexe 2), et cliniquement stabilisé depuis au moins 6 semaines avant l’inclusion (traitement stable et hors phase aigüe). NB: pour l'item 10 de la QIDS (concentration/prise de décision, ne coter que la prise de décision)
    *Critère A de TDAH de l'adulte selon DSM-5 (soit au moins 5 symptômes d'inattention et/ou d'hyperactivité/impulsivité)
    *Absence du critère D pendant l'enfance, l'adolescence et avant les troubles de l'humeur (c'est-à-dire absence de retentissement significatif avec réduction de la qualité du fonctionnement social, académique ou professionnel)
    *Présence du critère D actuellement (les symptômes ont un retentissement significatif avec réduction de la qualité du fonctionnement social, académique ou professionnel)
    - Sujet bénéficiant ou non d'un traitement pour les troubles de l'humeur autorisé :
    *stabilisateurs de l'humeur (lithium, valproate, lamotrigine, oxcarbazepine),
    *antidépresseurs (ISRS, IRSNa ≤150mg/j de venlafaxine et ≤60mg/j de duloxetine), benzodiazepines à doses stables depuis plus d'un mois (dose journalière maximum de équivalent à 10mg de diazepam).
    - Sujet bénéficiant ou non d'un traitement par méthylphénidate

    Groupe C : sujets sains contrôle
    - Sujet sans antécédent psychiatrique et neurologique
    E.4Principal exclusion criteria
    Common criteria for all groups
    - Subject with a contraindication to methylphenidate:
    * hypersensitivity to the active substance,
    * glaucoma
    * pheochromocytoma,
    * treatment with other indirect sympathomimetics or alpha sympathomimetics (oral and/or nasal), irreversible MAOIs
    * Hyperthyroidism or thyrotoxicosis,
    * Pre-existing cardiovascular disorders including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, congenital heart disease with hemodynamic impact, cardiomyopathy, myocardial infarction, arrhythmias and potentially life-threatening channelopathies (disorders caused by ion channel dysfunction),
    * Pre-existing cerebrovascular disorders, cerebral aneurysms, vascular abnormalities including vasculitis or stroke,
    * wheat allergy (other than celiac disease)
    - Unstabilized psychiatric disorders: severe depression, anorexia nervosa or anorexic disorder, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic or borderline personality disorder
    - Family history of ventricular arrhythmia, sudden death, particularly of cardiac origin, or unexplained death
    - Subjects with a contraindication to MRI: presence of a non-removable ferromagnetic body, prosthesis, pacemaker, medication delivered by an implanted pump, vascular clip or stent, heart valve or ventricular bypass
    - History that may affect brain anatomy or be related to an abnormality (neonatal distress, neurosurgical operation, comitiveness, stroke, head injury with loss of consciousness of more than 15 minutes and mental retardation)
    - History that may affect brain function (general anesthesia or electroconvulsive therapy within 3 months prior to inclusion)
    - Substance use disorder, according to DSM-5 criteria (excluding tobacco)
    - Pregnant women or, in women of childbearing age and capacity (not infertile), lack of effective contraception
    - Subjects participating in other research involving an investigational product
    - Nursing women
    - Serious or unstabilized somatic pathology.
    - Subject deprived of liberty, or under forced care
    - Subject under court protection
    - Subject under guardianship or curatorship
    - Impossibility to give the subject informed information (subject in an emergency situation, difficulties in understanding the subject, ...)
    - Subject in a period of exclusion defined by another protocol in progress
    Critères communs à tous les groupes

    - Sujet présentant une contre-indication au méthylphénidate :
    • hypersensibilité à la substance active,
    • glaucome,
    • phéochromocytome,
    • traitement par d’autres sympathomimétiques indirects ou des sympathomimétiques alpha (voies orale et/ou nasale), IMAO irréversibles
    • Hyperthyroïdie ou thyrotoxicose,
    • Troubles cardiovasculaires préexistants incluant hypertension sévère, insuffisance cardiaque, artériopathie occlusive, angine de poitrine, cardiopathie congénitale avec retentissement hémodynamique, cardiomyopathie, infarctus du myocarde, arythmies et canalopathies (troubles causés par un dysfonctionnement des canaux ioniques) pouvant potentiellement mettre en jeu le pronostic vital,
    • Préexistence de troubles cérébrovasculaires, anévrisme cérébral, anomalies vasculaires, y compris vascularite ou accident vasculaire cérébral,
    • allergie au blé (autre que la maladie cœliaque)
    - Troubles psychiatriques non stabilisés : dépression sévère, anorexie mentale ou troubles anorexiques, tendances suicidaires, symptômes psychotiques, troubles de l’humeur sévères, manie, schizophrénie, trouble de la personnalité psychopathique ou limite (borderline).
    - Antécédents familiaux d’arythmie ventriculaire, de mort subite notamment d’origine cardiaque ou de décès inexpliqué
    - Sujet ayant une contre-indication à la réalisation d’une IRM : présence de corps ferromagnétique non retirable, prothèse, pacemaker, médicaments délivrés par une pompe implantée, clip ou stent vasculaire, valve cardiaque ou dérivation ventriculaire
    - Antécédents susceptibles d’affecter l’anatomie cérébrale ou d’être liés à une anomalie (souffrance néonatale, opération neurochirurgicale, comitialité, AVC, traumatisme crânien avec perte de connaissance de plus de 15 minutes et retard mental)
    - Antécédents susceptibles d’affecter le fonctionnement cérébral (une anesthésie générale ou une électroconvulsivothérapie dans les moins de 3 mois précédant l’inclusion)
    - Trouble lié à l'usage de substance, selon critères DSM-5 (sauf tabac)
    - Femmes enceintes ou, chez les femmes en âge et en capacité de procréer (non stériles), absence d’une contraception efficace
    - Sujet participant à une autre recherche portant sur un produit expérimental
    - Femmes allaitantes
    - Pathologie somatique grave ou non stabilisée.
    - Sujet privé de liberté, ou en soins sous contrainte
    - Sujet sous sauvegarde de justice
    - Sujet sous tutelle ou sous curatelle
    - Impossibilité de donner au sujet des informations éclairées (sujet en situation d’urgence, difficultés de compréhension du sujet, …)
    - Sujet en période d’exclusion définie par un autre protocole en cours


    E.5 End points
    E.5.1Primary end point(s)
    Effect of methylphenidate on the task vs. rest in a region defined by its involvement in the cognitive task and its reactivity to methylphenidate. ROI (Region of Interest) analysis to maximize power.
    Effet du méthylphénidate sur le différentiel d'activation tâche vs. repos dans une région définie par son implication dans la tâche cognitive et sa réactivité au méthylphénidate. Analyse en ROI (Region of Interest) pour maximiser la puissance.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Between Day 14 and day 60 after the randomisation
    Entre J14 et J60 après la randomisation
    E.5.2Secondary end point(s)
    1- Decrease in rCBF (regional Cerebral Blood Flow) in the methylphenidate condition vs. placebo, in the different groups.
    2- Improved cognitive performance on tests of sustained attention, working memory and flexibility following the administration of methylphenidate, in the different groups.
    3- Stabilization of the power of the EEG spectrum in the low frequencies (delta (1-4Hz) and theta (4-8Hz)) in the methylphenidate condition vs. placebo.
    4-a MRI: Interaction group x treatment x task on cerebral activation linked to sustained attention and linked to the inhibition corresponding to each of these tasks.

    4-b EEG: Group x treatment x task interaction on the amplitude of the P300 wave linked to sustained attention (P300b) and linked to inhibition (P300a) corresponding to each of these tasks.
    1- Baisse du rCBF (regional Cerebral Blood Flow) dans la condition méthylphénidate vs. placebo, dans les différents groupes.
    2- Amélioration des performances cognitives aux tests d'attention soutenue, de mémoire de travail et de flexibilité suite à l’administration du méthylphénidate, dans les différents groupes.
    3- Stabilisation de la puissance du spectre EEG dans les basses fréquences (delta (1-4Hz) et theta (4-8Hz)) dans la condition méthylphénidate vs. placebo.
    4-a IRM : Interaction groupe x traitement x tâche sur l'activation cérébrale liée à l'attention soutenue et liée à l'inhibition correspondant à chacune de ces tâches.

    4-b EEG : Interaction groupe x traitement x tâche sur l'amplitude de l'onde P300 liée à l'attention soutenue (P300b) et liée à l'inhibition (P300a) correspondant à chacune de ces tâches.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Between Day 14 and day 60 after the randomisation
    Entre J14 et J60 après la randomisation
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety No
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LPLV
    LPLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months36
    E.8.9.1In the Member State concerned days60
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 80
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Yes
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state80
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-08-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-06-06
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 13:35:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA